Skip to content
Boca Raton City Online – Lifestyle
Author:
Arvinas Inc.
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
June 4, 2026
Arvinas to Present at Jefferies Global Healthcare Conference
May 29, 2026
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 5, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 3, 2026
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
March 18, 2026
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
March 11, 2026
Arvinas to Participate in Upcoming Investor Conferences
March 7, 2026
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
March 6, 2026
1
2
Next Page
→